Skip to main content

Research Repository

Advanced Search

Outputs (3)

Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply (2018)
Journal Article
Persson, M. S., Sarmanova, A., Doherty, M., & Zhang, W. (2018). Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply. Rheumatology, 57(11), 2060–2061. https://doi.org/10.1093/rheumatology/key269

MD reports a grant from AstraZeneca funding a non-drug PI-led study in Nottingham (Sons of Gout study) and honoraria for Advisory boards on osteoarthritis and gout for AstraZeneca, Grunenthal, Mallinckrodt, and Roche, outside the submitted work. WZ r... Read More about Comment on: Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials: Reply.

Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials (2018)
Journal Article
Persson, M. S., Sarmanova, A., Doherty, M., & Zhang, W. (2018). Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials. Rheumatology, 57(10), 1830-1837. https://doi.org/10.1093/rheumatology/key131

Objectives

The role of inflammation in OA is controversial and it is unclear whether suppressing inflammation with conventional or biologic DMARDs is effective. A systematic review and meta-analysis of randomized controlled trials (RCTs) was condu... Read More about Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials.